HOME >> BIOLOGY >> NEWS
JCI Table of Contents, September 15, 2003

ent of insulin action in the liver. Masato Kasuga and colleagues at Kobe University, Japan, have found that mice deficient in the hepatic enzyme PKC-lambda have increased overall insulin sensitivity, yet their blood glucose concentration remained within normal limits. The authors demonstrated a link between the altered expression of the sterol regulatory element-binding protein SREBP-1c gene and its target genes, and defective PKC-lambda signaling. Restoration of PKCl expression in the liver restored SREBP-1c expression and insulin sensitivity to normal. This study suggests that reagents that block PKC-lambda signaling specifically in the liver might consequently ameliorate insulin resistance.

TITLE: PKC-lambda in liver mediates insulin-induced SREBP-1c expression and determines both hepatic liver content and overall insulin sensitivity

AUTHOR CONTACT:
Masato Kasuga
Division of Diabetes and Digestive and Kidney Diseases, Kobe University Graduate School of Medicine, Kobe, Japan.
Phone: 81-78-382-5861
Fax: 81-78-382-2080
E-mail: kasuga@med.kobe-u.ac.jp

View the PDF of this article at: https://www.the-jci.org/press/18816.pdf


HATs off to Hop in cardiac hypertrophy

Histone acetylation, regulated by two antagonistic enzymes histone acetyltransferases (HATs) and histone deacetylases (HDACs) results in transcriptional changes and also plays a critical role in cardiac development and disease. A new study by Jonathan Epstein and colleagues from the University of Pennsylvania shows that overexpression of the atypical transcriptional co-repressor homeodomain-only protein (Hop) causes cardiac hypertrophy via recruitment of a class I HDAC. In contrast to the body of work on transcriptional mechanisms that drive cardiac hypertrophy, including class II HDACs, this report elucidates a novel gro
'"/>

Contact: Brooke Grindlinger
science_editor@the-jci.org
212-342-9006
Journal of Clinical Investigation
15-Sep-2003


Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology news :

1. JCI Table of Contents, 15 July 2004
2. JCI Table of Contents, January 15 2004
3. JCI Table of Contents, November 3, 2003
4. JCI Table of Contents, 1 October, 2003
5. JCI Table of Contents
6. JCI Table of Contents, 15 August 2003
7. JCI Table of Contents, May 1, 2003
8. JCI Table of Contents, April 1, 2003
9. JCI Table of Contents, March 14, 2003
10. JCI Table of Contents, January 2, 2003
11. JCI Table of Contents, December 2, 2002

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/8/2017)... Inc. (NASDAQ: AWRE ), a leading supplier of ... quarter and year ended December 31, 2016. ... compared to $6.9 million in the same quarter last year. ... million compared to $2.6 million in the fourth quarter of ... $0.5 million, or $0.02 per diluted share, which compares to ...
(Date:2/7/2017)... 7, 2017   MedNet Solutions , an innovative ... of clinical research, is pleased to announce that the ... innovative, highly flexible and award winning eClinical solution, is ... iMedNet is a proven Software-as-a-Service (SaaS) clinical research ... (EDC), but also delivers an entire suite of eClinical ...
(Date:2/3/2017)... 3, 2017  Texas Biomedical Research Institute announced that its ... Schlesinger as the Institute,s new President and CEO. Dr. ... 31, 2017. He is currently the Chair of the Department ... for Microbial Interface Biology at Ohio State University. ... President and CEO of Texas Biomed," said Dr. James ...
Breaking Biology News(10 mins):
(Date:2/23/2017)... Financial ... data, unaudited)Three Months Ended December 31,Twelve Months Ended December ... $           300$ ... Net Product Revenue 3539(10)%9498(4)%Kuvan Net ... Revenue  756025%297303(2)%Vimizim Net Product Revenue ...
(Date:2/23/2017)... 2017  MIODx announced today that it has ... technologies from the University of California, San Francisco ... monitor a patient for response to immune checkpoint ... second license extends the technology with a method ... have an immune-related adverse event (IRAE) from their ...
(Date:2/23/2017)... ROCHESTER, Minn. , Feb. 23, 2017 /PRNewswire/ ... a new product line of oncolytic vaccinia viruses ... Genelux Corporation as part of Genelux,s proprietary, vaccinia ... "We are excited to enter into a partnership ... time, selected oncolytic vaccinia viruses for use in ...
(Date:2/23/2017)... ... 23, 2017 , ... David Nolte, PhD accepted Purdue University’s ... Purdue Research Park of West Lafayette, Indiana. , The top commercialization award ... and success with, commercializing discoveries from Purdue research. “This award is truly an ...
Breaking Biology Technology:
Cached News: